Platelet Activating Factors

LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.

LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.

LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.

Methylcarbamyl PAF C-16 is a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma due to its resistance to degradation by PAF-AH. It is nearly equipotent with PAF C-16 in its ability to induce platelet

Methylcarbamyl PAF C-16 is a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma due to its resistance to degradation by PAF-AH. It is nearly equipotent with PAF C-16 in its ability to induce platelet

Methylcarbamyl PAF C-16 is a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma due to its resistance to degradation by PAF-AH. It is nearly equipotent with PAF C-16 in its ability to induce platelet

Methylcarbamyl PAF C-16 is a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma due to its resistance to degradation by PAF-AH. It is nearly equipotent with PAF C-16 in its ability to induce platelet

A C-8 analog of methylcarbamyl PAF C-16, a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma induces G1-phase cell cycle arrest, suggesting a potential role in the inhibition of oncogenic transformation.

A C-8 analog of methylcarbamyl PAF C-16, a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma induces G1-phase cell cycle arrest, suggesting a potential role in the inhibition of oncogenic transformation.

CD42b is a 145 kDa protein, which together with CD42c forma a 160 kDa heterodimer composed of an alpha-chain and a beta-chain, respectively. The subunits are linked together by a disulphide bond.

A cell-permeable STAT3 activator (EC₅₀ = 2 nM) that is more than 28,000-fold selective for STAT3 over STAT1 and NF-&kappaB increases the expression of BCL3, a known STAT3-dependent oncogene, and enhances STAT3 activation by the

General description Cluster of differentiation 36 (CD36) is an 88 kDa membrane transporter glycoprotein. It is also known as platelet glycoprotein IV or IIIb.